Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next

Simply Wall St.07-05 08:26

Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649974226?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-07-05 08:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649974226","market":"us","top_or_hot":-1,"title":"Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next","media":"Simply Wall St.","content":"<div>\n<p>Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-05 08:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba","article_id":"2649974226","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649974226","pubTimestamp":1783211218,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa Kreher to expand the Board to eight directors, securing a USPTO notice of allowance for a Keveyis patent expected to extend protection through 2039, and retiring about US$23,000,000 of its 8.00% Convertible Senior Notes due 2028.\nTaken together, these leadership changes, intellectual property...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","CUT":"Invesco MSCI Global Timber ETF","WOOD":"iShares S&P Global Timber &Fores","XERS":"Xeris制药","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","BK4007":"制药","AIPO":"Defiance AI and Power Infrastructure ETF","IP":"国际纸业","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4136":"纸材料包装","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","BK4588":"碎股"},"translate_title":"为什么Xeris Biopharma(XERS)在治理、知识产权和资产负债表变动后上涨7.7%-以及下一步是什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIPO":0.61,"CUT":0.6,"WOOD":0.6,"XERS":1.5,"IP":1.5},"content_text":"Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa Kreher to expand the Board to eight directors, securing a USPTO notice of allowance for a Keveyis patent expected to extend protection through 2039, and retiring about US$23,000,000 of its 8.00% Convertible Senior Notes due 2028. Taken together, these leadership changes, intellectual property progress, and debt reduction steps suggest management is actively reinforcing both oversight and the durability of its commercial portfolio. We’ll now examine how extending Keveyis intellectual property protection through 2039 could influence Xeris Biopharma’s existing investment narrative. We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.AdvertisementXeris Biopharma Holdings Investment Narrative RecapXeris Biopharma’s story still hinges on whether Recorlev, Gvoke, Keveyis, and the XP‑8121 pipeline can support sustained, profitable growth while funding innovation and managing debt. The new Keveyis patent allowance and partial retirement of the 8.00% Convertible Senior Notes do not materially change the near term reliance on this narrow portfolio, but they modestly ease the biggest near term concerns around exclusivity durability and balance sheet flexibility. Among the latest developments, the USPTO notice of allowance for a Keveyis patent, expected to extend protection through 2039, is most relevant to the current thesis. Stronger intellectual property around Keveyis helps support Xeris’s core revenue base at a time when investors are watching upcoming XP‑8121 milestones and the company’s ability to keep R&D and SG&A from outpacing sales growth. Yet, beneath this progress, there is still the underappreciated risk that Xeris’s heavy dependence on just three commercial products could leave investors exposed if... Read the full narrative on Xeris Biopharma Holdings (it's free!)Xeris Biopharma Holdings' narrative projects $440.9 million revenue and $84.8 million earnings by 2028. This requires 21.5% yearly revenue growth and a $116.8 million earnings increase from $-32.0 million today.Uncover how Xeris Biopharma Holdings' forecasts yield a $11.14 fair value, a 35% upside to its current price.Exploring Other PerspectivesXERS 1-Year Stock Price Chart Before this news, the most optimistic analysts were assuming revenue could reach about US$602 million and earnings about US$164 million by 2029, which is far more upbeat than the baseline view that emphasizes portfolio concentration and rising costs. As you weigh these contrasting expectations, remember that both sets of forecasts were made before the recent patent and governance moves, so your own view on how Xeris’s risks and opportunities are shifting really matters.Explore 3 other fair value estimates on Xeris Biopharma Holdings - why the stock might be worth just $11.14!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Xeris Biopharma Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Xeris Biopharma Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Xeris Biopharma Holdings' overall financial health at a glance.Interested In Other Possibilities?Opportunities like this don't last. These are today's most promising picks. Check them out now:Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.Uncover the next big thing with 20 elite penny stocks that balance risk and reward.Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649974226","isCrawlerRequest":true}